Patents Assigned to Merck
  • PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE
    Publication number: 20190375716
    Abstract: In its many embodiments, the present invention provides certain piperidine compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R3, L, R4, L1, Q, and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-? receptor (LXR?) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.
    Type: Application
    Filed: October 9, 2017
    Publication date: December 12, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael T. Rudd, Zhaoyang Meng, Jenny Wai, David Jonathan Bennett, Edward J. Brnardic, Nigel J. Liverton, Shawn J. Stachel, Yongxin Han, Paul Tempest, Jiuxiang Zhu, Xuewang Xu, Bin Zhu, Chuanman Huang
  • BISBENZOFURAN-FUSED INDENO[1,2-B]FLUORENE DERIVATIVES AND RELATED COMPOUNDS AS MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES (OLED)
    Publication number: 20190375757
    Abstract: The present invention relates to Bisbenzofuran-fused indeno[1,2-b]fluorene derivatives and related compounds as materials for organic electroluminescent devices (OLEDs).
    Type: Application
    Filed: November 22, 2017
    Publication date: December 12, 2019
    Applicant: Merck Patent GmbH
    Inventors: Rouven Linge, Lara-Isabel Rodriguez, Sebastian Meyer, Holger Heil
  • CTLA4 binders
    Patent number: 10501542
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: December 10, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Juha Punnonen, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Bjorn Victor, Robert A. Kastelein
  • Prefilled disposable injection device
    Patent number: 10500338
    Abstract: A drug delivery device comprising a drug container extending between a distal end and a proximal end and is capable of being compressed into a single plane; a body extending between proximal and distal ends comprising a hollow space for containing the drug container; and a plunger extending between proximal and distal ends, wherein the distal end of the plunger engages telescopically with the proximal end of the body, wherein the plunger comprises at least one pair of protrusions, wherein the protrusion is capable of compressing the drug container as the plunger moves towards the proximal end of the drug delivery device, by applying a force to the drug container that is perpendicular to the movement of the plunger.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: December 10, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventor: Annaniy Berenshteyn
  • Substituted bicyclic fused ring compounds as indoleamine-2,3-dioxygenase inhibitors
    Patent number: 10501458
    Abstract: Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the general formula (I) detailed within.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: December 10, 2019
    Assignees: Iomet Pharma Ltd., Merck Sharp & Dohme Corp.
    Inventors: Phillip M. Cowley, Alan Wise, Thomas J. Brown, Meredeth A. McGowan, Hua Zhou, Yongxin Han
  • SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease
    Patent number: 10500186
    Abstract: The present invention relates to certain SGLT-2 inhibitors, such as ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof, for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD). The present invention also relates to methods for preventing neuronal damage following the incidence of ischemic stroke and close-head traumatic brain injury in animals comprising the step of administering to an animal, in need of such treatment, a therapeutically effective amount of ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: December 10, 2019
    Assignees: Merck Sharp & Dohme Corp., Pfizer Inc.
    Inventors: Ramachandra G. Naik, Elizabeth S. Ommen, James Michael Rusnak, Steven G. Terra
  • Piperidine derivatives and liquid-crystalline medium
    Patent number: 10501691
    Abstract: Disclosed are compounds of the formula I, liquid-crystalline media comprising the compounds of formula I, and the use of these liquid-crystalline media in liquid-crystal displays.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: December 10, 2019
    Assignee: MERCK PATENT GMBH
    Inventors: Achim Goetz, Rocco Fortte, Martin Engel, Sabrina Maag, Thorsten Kodek
  • ANTIDIABETIC HETEROCYCLIC COMPOUNDS
    Publication number: 20190367495
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    Type: Application
    Filed: December 1, 2017
    Publication date: December 5, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael Miller, Harry R. Chobanian, Shuwen He, Jinsong Hao, Barbara Pio
  • ORGANIC ELECTROLUMINESCENT DEVICE
    Publication number: 20190372025
    Abstract: The present invention relates to an organic electroluminescent device comprising a hole-injection layer comprising a metal complex as a main component and a method for producing the organic electroluminescent device.
    Type: Application
    Filed: February 27, 2018
    Publication date: December 5, 2019
    Applicants: Merck Patent GmbH, Merck Patent GmbH
    Inventors: Ilona STENGEL, Frank VOGES, Teresa MUJICA-FERNAUD, Henning SEIM
  • SYSTEM AND APPARATUS FOR DISCHARGING STERILE MEDIA
    Publication number: 20190367864
    Abstract: The invention relates to a tubing device (40) for sterile media comprising a container (54) for storing sterile media, a discharge port (52) for discharging liquid sterile media, an inlet port (41) for introducing fluid into the tubing device and a multiple-way-connector (50), wherein the multiple-way-connector (50) is connected to the container (54), the discharge port (52) and the inlet port (41), and an apparatus (80) for preparing, mixing and discharging a sterile medium for use with a tubing device (40), comprising a water inlet port (41) for introducing water, a water outlet port (87) configured to be connected to the inlet port (41) of the tubing device (40), a fluid pump (82) for conveying the fluid, the fluid pump (82) is connected to the fluid inlet port (81) and the water outlet port (87) and a container support (88) for supporting the container (54) of the tubing device (40).
    Type: Application
    Filed: January 15, 2018
    Publication date: December 5, 2019
    Applicant: Merck Patent GmbH
    Inventors: Stephane OLIVIER, Gaetan BOUR
  • SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS
    Publication number: 20190365727
    Abstract: The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1 is as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: January 23, 2018
    Publication date: December 5, 2019
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Tao Yu, John A. McCauley, Alan Whitehead, James M. Apgar, Izzat T. Raheem, Guizhen Dong, Sherman T. Waddell, Hong Li
  • Co-agonists of the glucagon and GLP-1 receptors
    Patent number: 10493125
    Abstract: Co-agonists of the glucagon and GLP-1 receptors are described.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: December 3, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Anandan Palani, Paul E. Carrington, Antonello Pessi, Armin Lahm, Elisabetta Bianchi, Anna Demartis
  • Heteroaryl compounds as BTK inhibitors and uses thereof
    Patent number: 10493073
    Abstract: The present invention relates to pyrimidine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: December 3, 2019
    Assignee: Merck Patent GmbH
    Inventors: Hui Qiu, Richard D. Caldwell, Lesley Liu-Bujalski
  • Compounds and organic electronic devices
    Patent number: 10497877
    Abstract: The present invention relates to certain fluorenes, to the use of the compounds in an electronic device, and to an electronic device comprising at least one of these compounds. The present invention furthermore relates to a process for the preparation of the compounds and to a formulation and composition comprising one or more of the compounds.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: December 3, 2019
    Assignee: Merck Patent GmbH
    Inventors: Teresa Mujica-Fernaud, Elvira Montenegro, Amir Hossain Parham, Arne Buesing, Frank Voges
  • Metal Complexes Containing Allyl Ligands
    Publication number: 20190359640
    Abstract: Metal complexes containing substituted allyl ligands and methods of using such metal complexes to prepare metal-containing films are provided.
    Type: Application
    Filed: August 31, 2017
    Publication date: November 28, 2019
    Applicant: MERCK PATENT GMBH
    Inventors: Bin XI, Joby ELDO, Charles DEZELAH, Ravi KANJOLIA, Guo LIU
  • POLYMERISABLE LIQUID CRYSTAL MATERIAL AND POLYMERISED LIQUID CRYSTAL FILM
    Publication number: 20190359889
    Abstract: The invention relates to a polymerisable LC material comprising at least one di- or multireactive mesogenic compound and at least one compound of formula I, in which the parameter R1, A1, Z2, Sp, P, p1, p2, L1, L2, r1, r2 and Ra have one of the meanings as given in claim 1 and to a compound of formula 1, as such. Furthermore, the present invention relates also to a method for the preparation of a polymerisable LC material, a polymer film obtainable from the corresponding polymerisable LC material, to a method of preparation of such polymer film, and to the use of such polymer film and said polymerisable LC material for optical, electro-optical, decorative or security devices.
    Type: Application
    Filed: September 12, 2017
    Publication date: November 28, 2019
    Applicant: MERCK PATENT GMBH
    Inventors: Stephen MULCAHY, Iain GARDINER, Helmut HAENSEL, Graziano ARCHETTI
  • Materials for organic electroluminescent devices
    Patent number: 10487262
    Abstract: The present invention relates to a compound of formula (I) or (II), which is suitable for use as functional material in an electronic device, in particular as emitter material in an organic electroluminescent device.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: November 26, 2019
    Assignee: Merck Patent GmbH
    Inventors: Beate Burkhart, Holger Heil, Lara-Isabel Rodriguez, Sebastian Meyer, Amandine Darsy, Rouven Linge
  • Formulations and electronic devices
    Patent number: 10490747
    Abstract: A formulation comprising at least one solvent and at least two different functional compounds of formula (I) AB]k??(I) wherein A is a functional structural element, the structural element serving as host material, as a unit that has hole-injection and/or hole-transport properties, as a unit t at has electron-injection and/or electron-transport properties, as a unit which has light-emitting properties, or as a unit which improves the transfer from the singlet state to the triplet state of light-emitting compounds; B is a solubility-promoting structural element; and k is an integer in the range from 1 to 20; the molecular weight of the functional compound is at least 550 g/mol, and the solubility-promoting structural element B conforms to the general formula (L-I)
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: November 26, 2019
    Assignee: Merck Patent GmbH
    Inventors: Rémi Manouk Anèmian, Susanne Heun, Thomas Eberle, Philipp Stoessel, Aurélie Ludemann, Dietmar Kunkel
  • Anti-PD-L1 antibodies and uses thereof
    Patent number: 10487147
    Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: November 26, 2019
    Assignee: Merck Patent GmbH
    Inventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna
  • Pump for fluids
    Patent number: D868839
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: December 3, 2019
    Assignee: Merck Patent GmbH
    Inventors: Fabrice Comini, Patrick Chateau, Camille Chouard